Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexFemale
Age18-54
SponsorQueen's Medical Center
About this trial
This project aims to investigate if the contraceptive method, Phexxi, causes changes to the composition of the vaginal microbiome. The investigators hypothesize that regular use of Phexxi will cause increased colonization of lactic acid-producing lactobacilli, which could have positive effects in the way of preventing recurrent episodes of BV and candida infections.
Eligibility criteria
Qualifiers
Age 18-54
Female
Pre-menopausal
Can speak and read in English
Disqualifiers
Pregnant or trying to become pregnant
Post-menopausal
Using NuvaRing device
A past medical history of kidney disease, recurrent UTI, and/or urinary tract abnormalities
Trial design
Treatments tested in this trial
- Phexxi
Treatment groups
22 Participants
are divided into 1 treatment groupSponsors and collaborators
Queen's Medical Center
Lead sponsor
University of Hawaii Foundation
Collaborator
Source ClinicalTrials.gov